Conflict in the Middle East continues to lead many of the front pages. Iranian clerics named Ayatollah Ali Khamenei's son Mojtaba Khamenei as the new Supreme Leader, in what the Times describes as a "challenge to Trump". It cites the US President's previous comments that the 56-year-old "would not be an acceptable new leader" of Iran. Mojtaba Khamenei "may already be injured" following recent US-I...
Conflict in the Middle East continues to lead many of the front pages. Iranian clerics named Ayatollah Ali Khamenei's son Mojtaba Khamenei as the new Supreme Leader, in what the Times describes as a "challenge to Trump". It cites the US President's previous comments that the 56-year-old "would not be an acceptable new leader" of Iran. Mojtaba Khamenei "may already be injured" following recent US-Israeli strikes, the paper adds.
Key Points The company's "growth portfolio" is offsetting declines in "legacy" treatments. It also showed marked progress in two of its developmental programs. 10 stocks we like better than Bristol Myers Squibb › Ever-busy global pharmaceutical company Bristol Myers Squibb (NYSE: BMY) had quite an active February. Since much of the news coming from it was positive, investors were largely bullish o...
Key Points The company's "growth portfolio" is offsetting declines in "legacy" treatments. It also showed marked progress in two of its developmental programs. 10 stocks we like better than Bristol Myers Squibb › Ever-busy global pharmaceutical company Bristol Myers Squibb (NYSE: BMY) had quite an active February. Since much of the news coming from it was positive, investors were largely bullish on its future, even after price cuts to its No. 1 drug kicked in. This optimism was reflected in a share price rise of over 13% over the month. Growth where it counts Near the start of February, Bristol Myers Squibb published its final earnings report for 2025. It managed to grow its fourth-quarter revenue, albeit modestly, by 1% year over year to $12.5 billion. We can't say the same for net income not under generally accepted accounting principles (GAAP), which sank at a double-digit rate of almost 24% to $2.6 billion, or $1.26 per share. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » That sounds a bit scary, but it's the latest chapter in a story that's been playing out for the healthcare giant for some time. It still derives much of its coin from the so-called "legacy portfolio," its collection of medicines that have either hit their patent cliffs or are rapidly approaching them. This includes the above-mentioned drug, blood thinner Eliquis, the net profits for which are shared with the company's big pharma partner Pfizer. In the quarter, legacy's revenue dived by 15% to slightly more than $5.1 billion. The contrast with Bristol Myers Squibb's very promising "growth portfolio" of drugs that have some time before the cliff looms is stark. Led by blockbuster cancer drug Opdivo, growth's growth (sorry) for the quarter was 16%, rising to nearly $7.4 billion. Regardless, the company easily exceeded the cons...
Key Points The Federal Reserve cut its key rates twice during the period. It probably won't repeat that move anytime soon, however. 10 stocks we like better than UWM Holdings › Investors in mortgage lender UWM Holdings (NYSE: UWMC) had a February nearly as unpleasant as the weather that month. The company's shares lost a bit over 10% of their value in the short month, despite the company reporting...
Key Points The Federal Reserve cut its key rates twice during the period. It probably won't repeat that move anytime soon, however. 10 stocks we like better than UWM Holdings › Investors in mortgage lender UWM Holdings (NYSE: UWMC) had a February nearly as unpleasant as the weather that month. The company's shares lost a bit over 10% of their value in the short month, despite the company reporting record loan volumes in its fourth quarter. A major home financier UWM is the indirect parent company of Universal Wholesale Mortgage, which, as its name implies, provides mortgages to third-party sellers (mainly brokers). UWM controls the largest wholesaler, so its size and scope are considerable. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The company posted its fourth-quarter and full-year results toward the end of the month, divulging that it originated $49.6 billion in home loans during the former period. This was up significantly from the $38.7 billion it earned in the same quarter of 2024. That filtered down to revenue of just over $945 million, for a robust year-over-year gain of 31%. As for profitability, net income not under generally accepted accounting practices (GAAP) zoomed nearly four times higher to more than $130 million, or $0.08 per share. Analysts were expecting a higher bottom-line bounce; however, their collective estimate for non-GAAP (adjusted) net income was $0.09 per share. On a brighter note, UWM beat on revenue, as the average prognosticator expectation for that line item was barely over $754 million. UWM benefited greatly from not one, but two cuts to the Federal Reserve's key interest rate during the quarter. This significantly ramped up refinancing volume, which almost doubled from both the previous and the year-ago quarters to $30.7 billion. Surges in key fundamentals d...
Palantir Technologies (PLTR +3.03%) stock has lost 30% of its value from its 52-week high that it hit in early November last year, when shares were trading at just over $200. The stock's pullback in recent months is the result of an expensive valuation, as well as the recent sell-off in software stocks following artificial intelligence (AI) start-up Anthropic's launch of a new AI tool that reporte...
Palantir Technologies (PLTR +3.03%) stock has lost 30% of its value from its 52-week high that it hit in early November last year, when shares were trading at just over $200. The stock's pullback in recent months is the result of an expensive valuation, as well as the recent sell-off in software stocks following artificial intelligence (AI) start-up Anthropic's launch of a new AI tool that reportedly poses a threat to traditional software companies. But will Palantir stock be able to overcome the recent weakness and reclaim the $200 milestone once again? Let's find out. Palantir Technologies stock isn't cheap despite the pullback, but that's half the story Palantir is trading at 218 times trailing earnings and 113 times forward earnings right now. Even the sales multiple of 79 is extremely expensive. So, it is easy to see why the stock has been under pressure in recent months despite reporting robust growth in both revenue and earnings. Expand NASDAQ : PLTR Palantir Technologies Today's Change ( 3.03 %) $ 4.62 Current Price $ 157.29 Key Data Points Market Cap $376B Day's Range $ 150.34 - $ 161.43 52wk Range $ 66.12 - $ 207.52 Volume 3.6M Avg Vol 48M Gross Margin 82.37 % Palantir's revenue in the fourth quarter of 2025 increased 70% year over year to $1.4 billion. Its earnings increased by almost 80% year over year to $0.25 per share last quarter. Palantir believes that it can maintain its impressive growth in 2026 as well. The company has guided for a 60% increase in revenue this year to $7.2 billion. However, it could easily do better than that. After all, Palantir ended 2025 with $8.6 billion in remaining deal value (RDV). The metric, which refers to the total value of Palantir's contracts yet to be fulfilled at the end of a quarter, increased by 91% from the year-ago period. So, Palantir's revenue pipeline grew much faster than its actual revenue, driven by the rapid adoption of its AI solutions. Palantir's AI software platform enables customers to enhance produc...
"But for the people we are seeing who can now do a bit of exercise, they can walk, they feel they are getting their life back - at the moment, it does seem to be worth it for them."
"But for the people we are seeing who can now do a bit of exercise, they can walk, they feel they are getting their life back - at the moment, it does seem to be worth it for them."
(RTTNews) - The Singapore stock market has moved higher in three straight sessions, collecting more than 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,325-point plateau although it's likely to run out of steam on Wednesday. The global forecast for the Asian markets is a mixed bag, with weakness among the financials and oil companies likely countered by s...
(RTTNews) - The Singapore stock market has moved higher in three straight sessions, collecting more than 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,325-point plateau although it's likely to run out of steam on Wednesday. The global forecast for the Asian markets is a mixed bag, with weakness among the financials and oil companies likely countered by support from the technology shares. The European markets were down and the U.S. bourses were mixed and the Asian markets figure to split the difference. The STI finished modestly higher on Tuesday as gains from the industrials and trusts were capped by weakness from the property sector. For the day, the index added 12.14 points or 0.37 percent to finish at 3,326.28 after trading between 3,309.68 and 3,329.24 Among the actives, CapitaLand Integrated Commercial Trust surged 1.03 percent, while City Developments slid 0.19 percent, Comfort DelGro slumped 0.74 percent, DBS Group collected 0.31 percent, Hongkong Land sank 0.62 percent, Keppel DC REIT added 0.56 percent, Mapletree Pan Asia Commercial Trust spiked 0.81 percent, Mapletree Industrial Trust gained 0.47 percent, Mapletree Logistics Trust rallied 0.76 percent, Oversea-Chinese Banking Corporation jumped 0.70 percent, SATS stumbled 1.04 percent, Seatrium Limited climbed 0.68 percent, SembCorp Industries advanced 0.60 percent, Singapore Technologies Engineering soared 0.98 percent, SingTel gathered 0.38 percent, Thai Beverage retreated 1.06 percent, Wilmar International perked 0.32 percent, Yangzijiang Financial tumbled 1.43 percent, Yangzijiang Shipbuilding rose 0.40 percent and Emperador, Genting Singapore, CapitaLand Investment and Keppel Ltd were unchanged. The lead from Wall Street remains divergent as the major averages opened mixed and finished the same way. The Dow tumbled 299.05 points or 0.76 percent to finish at 39,112.16, while the NASDAQ rallied 220.84 points or 1.26 percent to close at 17,717.65 and the S&P 50...
Highly specialized robotics company Teradyne (TER 10.51%) was a popular stock on the market in February. A rally kicked off following the company's latest earnings report on Feb. 2, with the estimates-trouncing period setting the tone for the stock across the rest of the month. From the first trading day to the last in February, Teradyne's shares gained almost 33%. Advancing with AI Teradyne's fou...
Highly specialized robotics company Teradyne (TER 10.51%) was a popular stock on the market in February. A rally kicked off following the company's latest earnings report on Feb. 2, with the estimates-trouncing period setting the tone for the stock across the rest of the month. From the first trading day to the last in February, Teradyne's shares gained almost 33%. Advancing with AI Teradyne's fourth quarter of 2025 was outstanding in many respects, not least because the robtotics company grew both revenue and profitability at impressive rates. The former metric surged 44% year over year to $1.08 billion. Not surprisingly, the company's semiconductor diagnostics products accounted for the leading revenue source, bringing in $883 million. Its other two product categories (product and robotics testing) contributed $110 million and $89 million, respectively. All three posted top-line gains over the previous quarter, the company said. The semiconductor segment is hot right now due to consistently heavy demand for artificial intelligence (AI). Chips that can handle AI workflows require vigorous testing, which plays beautifully into the hands of a diagnostics specialist like Teradyne. The company's bottom line also improved dramatically, with net income not in accordance with generally accepted accounting principles (GAAP) rocketing almost 83% higher to $283 million, or $1.80 per share. Those two headline figures were miles above the consensus analyst estimates. Collectively, pundits tracking Teradyne stock were modeling revenue of just over $969 million, and non-GAAP (adjusted) net income of only $1.36 per share. Management expects the growth train to keep thundering down the tracks. For its current (first) quarter, the company expects revenue of $1.15 billion to $1.25 billion and adjusted net earnings per share (EPS) of $1.89 to $2.25. Again, both are substantially above the consensus prognosticator forecasts: $942 million for the former line item and $1.25 per share fo...
Key Points AI was helping power the company's fundamentals, a trend that was abundantly clear towards the end of 2025. A clutch of analysts raised their price targets on its shares too. 10 stocks we like better than Teradyne › Highly specialized robotics company Teradyne (NASDAQ: TER) was a popular stock on the market in February. A rally kicked off following the company's latest earnings report o...
Key Points AI was helping power the company's fundamentals, a trend that was abundantly clear towards the end of 2025. A clutch of analysts raised their price targets on its shares too. 10 stocks we like better than Teradyne › Highly specialized robotics company Teradyne (NASDAQ: TER) was a popular stock on the market in February. A rally kicked off following the company's latest earnings report on Feb. 2, with the estimates-trouncing period setting the tone for the stock across the rest of the month. From the first trading day to the last in February, Teradyne's shares gained almost 33%. Advancing with AI Teradyne's fourth quarter of 2025 was outstanding in many respects, not least because the robtotics company grew both revenue and profitability at impressive rates. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The former metric surged 44% year over year to $1.08 billion. Not surprisingly, the company's semiconductor diagnostics products accounted for the leading revenue source, bringing in $883 million. Its other two product categories (product and robotics testing) contributed $110 million and $89 million, respectively. All three posted top-line gains over the previous quarter, the company said. The semiconductor segment is hot right now due to consistently heavy demand for artificial intelligence (AI). Chips that can handle AI workflows require vigorous testing, which plays beautifully into the hands of a diagnostics specialist like Teradyne. The company's bottom line also improved dramatically, with net income not in accordance with generally accepted accounting principles (GAAP) rocketing almost 83% higher to $283 million, or $1.80 per share. Those two headline figures were miles above the consensus analyst estimates. Collectively, pundits tracking Teradyne stock were modeling revenue of ...